BRIEF

on Altius Bioventures

Altius Bioventures Launches The CGT Industry Atlas, Mapping the Innovation Landscape

VANCOUVER, BC / ACCESSWIRE / September 10, 2024 / Altius Bioventures has announced the release of its CGT Industry Atlas, a comprehensive guide to the cell and gene therapy technologies landscape. The Atlas covers everything from starting material collection to therapy manufacturing and clinical delivery, categorizing the sector into seven core elements.

"The CGT Industry Atlas is an essential guide for investors, innovators, and executives," said Emmanuel Grillot, Managing Director at Altius Bioventures. It aims to provide clarity and insight, helping stakeholders identify synergies, strategic partnerships, and growth opportunities.

The Atlas offers a structured view of enabling tools and technologies, highlighting key areas of innovation. It sets emerging technologies in the context of industry initiatives like reducing vein-to-vein time, increasing patient accessibility, and personalizing medicine.

"Our objective is to simplify the complexities of cell and gene therapy technologies," said Lee Buckler, partner at Altius Bioventures. The Atlas aims to create an industry-standard guide while showcasing rapidly evolving technologies like AI/ML, -omics, and automation.

R. E.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Altius Bioventures news